ArticleJournal of ovarian research2026
Two compound heterozygous MEIOSIN (likely) pathogenic variants cause female infertility with premature ovarian insufficiency through the disruption of meiosis-related gene transcription.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPremature ovarian insufficiency (POI) is a major contributor to female infertility; however, its genetic basis remains insufficiently understood. MEIOSIN is crucial for initiating meiosis by activating a subset of key meiotic genes that regulate the transition from mitosis to meiosis in mammalian germ cells. Recent studies suggest that biallelic MEIOSIN variant may contribute to POI in humans, yet further analysis is required to confirm and clarify this role.
methodsTo identify potential pathogenic variants associated with POI, whole-exome sequencing was conducted in the affected individuals, followed by Sanger sequencing for variant validation. To evaluate the functional consequences of these variants, a series of in vitro assays was performed, including Western blotting, immunostaining, and structural modeling of mutant proteins. Additionally, a dual-luciferase reporter assay was utilized to assess whether the identified variants influenced the transcriptional activity of MEIOSIN.
resultsTwo compound heterozygous variants in MEIOSIN-c.980T > C (p.Leu327Pro) and c.1068_1092del (p.His356fs*14)-were identified in two affected sisters, with the latter representing a novel variant. Sanger sequencing confirmed that the two variants were inherited from each parent, thereby establishing compound heterozygosity. Functional characterization revealed that the frameshift variant resulted in a truncated MEIOSIN protein with aberrant intracellular localization. While the missense variant did not impact MEIOSIN expression or localization, it disrupted the protein's 3D structure. Furthermore, dual-luciferase assays demonstrated that both variants impaired MEIOSIN's transcriptional regulation of downstream meiotic genes. According to the ACMG/AMP guidelines, the frameshift variant was classified as pathogenic, while the missense variant was classified as likely pathogenic.
conclusionThese findings provide compelling evidence that pathogenic biallelic variants in MEIOSIN represent a recurrent genetic cause of POI in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.